Earnings

High Tide Q2 2026 Earnings Call Transcript – High Tide (NASDAQ:HITI)

On Tuesday, High Tide (NASDAQ:HITI) discussed second-quarter financial results during its earnings call. The full transcript is provided below.

Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more.

Access the full call at https://app.webinar.net/49ONKGgKpM6

Summary

Full Transcript

Jenny (Operator)

Good morning. My name is Jenny and I will be your conference operator today. At this time, I would like to welcome everyone to High Tide Inc. second fiscal quarter 2026 audited financial and operational results conference call. All lines have been placed on mute. to prevent any background noise. After the speaker’s remarks, there will be a question and answer session. Instructions will be provided at that time for you to queue up for questions. I will now turn the call over to your host.

Carter

Thank you, operator. Good morning everyone and welcome to High Tide, Inc. quarterly earnings call. Joining me on the call today are Mr. Raj Grover, President and Chief Executive Officer, and Mr. Mike Mahajan, Chief Financial Officer. On June 15, 2026, the Company released financial and operational results for the fiscal quarter that ended April 30, 2026. Before we begin, please let me remind you that during the course of this conference call, High Tide’s management may make statements including with respect to management’s expectations or estimates of future performance.

All such statements, other than statements of historical facts, constitute forward looking information or forward looking statements within the meaning of the applicable security laws and are based on assumptions, expectations, estimates and projections as of the date hereof. Specific forward looking statements include without limitation all disclosures regarding future results of operations, economic conditions and anticipated courses of action.

For more information on the Company’s risks and uncertainties related to forward looking statements, please refer to the Company’s press release dated June 15, 2026, our latest annual information form and our latest management discussion and analysis, each filed with securities regulatory authorities at sedarplus.ca or on Edgar at www.sec.gov/edgar or on the company’s website at www.hightideinc.com and which are hereby incorporated by reference herein.

Although these forward looking statements reflect management’s current beliefs and reasonable assumptions based on the currently available information to management as of the date hereof, we cannot be certain that the actual results will be consistent with the forward looking statements. In the future. There can be no assurance that actual outcomes will not differ materially from these results. Accordingly, we caution you not to place undue reliance upon such forward looking results for any reconciliation of non IFRS measures measured and discussed.

Please consult our latest management discussion and analysis filed on Sedar plus and Edgar. It is now my pleasure to introduce Mr. Raj Grover, President and Chief Executive Officer of High tide. Thank you, Mr. Grover. You may begin.

Raj Grover (President and Chief Executive Officer)

Thank you, Carter and good morning everyone. Welcome to High Tide Inc. financial results conference call for the second fiscal quarter that ended April 30, 2026. I’ll begin with some high level comments about the quarter and our strategy before Mayank dives deeper into the financials. The High Tide team built on top of the strength we demonstrated in Q1 and took the company to new heights in Q2 as it is typically the slowest quarter from a seasonal perspective and given three fewer days, Q2 is usually our weakest quarter.

I’m extremely proud to report that not only was this our best Q2 ever, but looking at the financial highlights, it was the best overall quarter we have ever reported to our shareholders. There was strength across the board as we set new all time records in revenue, gross profit, income from operations and adjusted ebitda. These all time highs were supported by both our core bricks and mortar Canadian cannabis business as well as ReMaxion, which generated record levels of tonnage revenue, gross margin and adjusted EBITDA in Q2.

Let’s drill into the highlights. Our consolidated revenue for the quarter was $179.3 million, putting us on an annualized pace well ahead of $700 million. Revenue was up 30% year over year, growing at its fastest pace in 11 quarters. Our bricks and mortar segment saw cannabis, hemp derived products and other revenue post an 8% gain year over year at $48.4 million. Our consolidated gross profit set an all time record. This grew even faster than revenue, up 36% year over year, representing the fastest pace of growth in 12 quarters.

Sequentially, gross profit was up 9% despite this quarter having three fewer days to make sales at 27%. Our consolidated gross profit margin set an eight quarter high and was up over 200 basis points. Sequentially our bricks and mortar segment posted a sequential gain, but the real standout was our medical cannabis distribution segment which generated gross profit margin of 27% which was more than double the 12% it generated in Q1. Since we first disclosed our plans to enter the German medical cannabis market, we had identified our unparalleled ability to be able to procure cannabis at best in class terms and now I am thrilled to see this showing up in our financial results. Income from operations was a record $6.1 million in Q2, up a truly impressive 554% year over year and 157% sequentially, highlighting the degree of operating leverage in the business and and the extent to which we run a tight ship. Adjusted EBITDA of $13.9 million was an all time high. This was up 73% year over year, marking its fastest pace of growth in nine quarters and up 21% sequentially, our adjusted EBITDA margin of 8% set an eight quarter high again.

While Q2 is typically the seasonally slowest quarter of the year and and with three fewer days, I am proud that we were still able to hit key milestones of positive net income and free cash flow this quarter. Adjusted for non cash fair value charges of derivative liabilities and excluding non controlling interest, we generated net income of $0.01 per fully diluted share, which was a huge reversal from a loss of 4 cents in the prior year and a loss of 2 cents.

Sequentially. Excluding the non cash impact from derivative liabilities which largely arise from the outperformance of ReMaxion’s results, we believe we are at the point where we can sustainably generate positive net income going forward. Free cash flow was $1.5 million in Q2. While this was lower than what we had generated in Q1 this year and Q2 last year, the devil is in the details Cash flow from operating activities prior to changes in non cash working capital was $8.8 million, which was a seven quarter high.

However, setting the multiple all time records I just reviewed required investments in working capital to grow the business. Specifically, we invested $4.3 million in working capital, which was the largest quarterly investment we’ve made during the past six years. As we always say, we believe it’s most appropriate to look at a longer period of free cash flow to smooth out such variability. From working capital changes over the past 12 months, we have now generated $13.4 million in free cash flow.

All of this execution doesn’t just happen by accident or because a rising tide is lifting all boats across the industry. That’s clearly not the case when you compare our performance versus our peers. We work hard and exceed our own expectations ahead of our own internal timelines. Having been legally selling to cannabis consumers for approaching 20 years now, we understand all aspects of our ever changing business very well. We don’t follow the herd.

We don’t sit on our hands. As markets evolve, we’ve made bold moves, but thoughtful and calculated ones, not rash decisions. And these have been paying off. Whether it’s a differentiated discount club model or our entry into the German medical cannabis market. Our innovative moves have carved out a successful winning strategy and others are struggling to play catch up later. The ReMaxion Transaction closed on September 2, 2025 and we have used our unparalleled ability to procure cannabis from Canada to boost the company’s results, just like we said we would.

Revenue for the two months it contributed to Q4 results was just under $10 million, averaging $5 million a month in Q1. Remexian’s revenue was $25 million, averaging over $8 million a month this quarter, ReMaxion generated $31.6 million, averaging over $10.5 million a month. In terms of volumes, ReMaxion sold 7.6 tons of medical cannabis during the three months ended March 2026 with which was up 85% from the three months ended September 2025 and we have more than doubled our market share in the two quarters since the transaction to 14.1% from 6.5%.

We believe we are heading towards 20% market share in Germany in the long term. Scaling the top line and boosting market share was an important element of our German strategy and I’m thrilled with how well and how quickly it is playing out. But the other key component of our strategy was how we could get better terms given our relationships with licensed producers, not just volume for volume’s sake. Again, success here was already demonstrated this quarter.